预约演示
更新于：2026-08-07
atebimetinib
更新于：2026-08-07
概要
基本信息
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
关联
2
项与 atebimetinib 相关的临床试验NCT07562152
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
开始日期2026-06-05 |
申办/合作机构 |
NCT05585320
A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest.
开始日期2022-10-31 |
申办/合作机构 |
100 项与 atebimetinib 相关的临床结果
登录后查看更多信息
100 项与 atebimetinib 相关的转化医学
登录后查看更多信息
100 项与 atebimetinib 相关的专利（医药）
登录后查看更多信息
180
项与 atebimetinib 相关的新闻（医药）2026-08-07
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 -
- Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and
over 30
study locations
posted
to date -
- Peer-reviewed publication in Cancer Research details atebimetinib’s broad, durable preclinical activity, and favorable tolerability across RAS- and RAF-mutant tumors, along with preservation of body mass -
- Ended Q2 2026 with
$182.7 million
in cash, cash equivalents and marketable securities with anticipated runway into 2029 -
ezstandalone.cmd.push(function () {
ezstandalone.showAds(131);
});
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
“At a time when first-line pancreatic cancer patients finally have treatment options, the 17.3 month median overall survival reported at ASCO for atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in our single-arm Phase 2a study stands out as potentially best-in-class. Equally important in our Phase 2a data presented at ASCO is that 84% of evaluable patients treated with atebimetinib + mGnP were weight stable or gained weight at three months, and only two categories of treatment related adverse events occurred at a grade 3 or higher in at least 10% of patients. In other words, debilitating side effects may not have to be a given for patients. With over 30 study locations already posted on clinicaltrials.gov, and newly published preclinical data in the peer reviewed journal
Cancer Research
supporting atebimetinib’s unique mechanism of action, we believe our Phase 3 MAPKeeper 301 study represents a compelling and differentiated option for first-line pancreatic cancer patients.”
Recent Corporate Highlights:
Dosing patients in the Company’s pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer.
In June, Immuneering announced it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer patients.
Presented compelling Phase 2a data at the ASCO 2026 Annual Meeting, demonstrating 17.3 month median overall survival and a favorable tolerability pro 55 first-line pancreatic cancer patients, together with 84% of evaluable patients weight stable or gaining weight at 3 months.
The Phase 2a trial is evaluating atebimetinib in combination with mGnP with results reported as of an April 24, 2026 data cutoff.
Appointed Andrew Gengos as Chief Financial Officer.
In June, Immuneering announced the appointment of Andrew Gengos as Chief Financial Officer. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion. Mr. Gengos will oversee financial strategy, capital allocation, investor relations, business development, and corporate development activities.
Published new findings in
Cancer Research
detailing atebimetinib’s broad, durable preclinical activity and favorable tolerability across RAS- and RAF-mutant tumors via Deep Cyclic Inhibition.
In July, Immuneering announced the publication of an article in
Cancer Research
, a leading peer-reviewed journal of the American Association for Cancer Research, characterizing the differentiated mechanism and broad preclinical activity of atebimetinib. The article, “Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF-Bypass,” reports that atebimetinib demonstrated broad antitumor activity across RAS- and RAF-mutant models while resisting RAF-mediated bypass signaling, a key mechanism associated with resistance to other MEK inhibitors. Atebimetinib’s ability to preserve body mass in a preclinical model of cancer cachexia was also highlighted in the article.
Presented Genetic Data at AACR demonstrating mechanism to improve durability and survival, supporting use of atebimetinib in first-line pancreatic cancer and beyond.
In April, Immuneering presented new genetic data in a poster presentation demonstrating a key mechanism that may improve durability and survival, supporting the use of atebimetinib as a first-line treatment in pancreatic cancer and beyond. The circulating tumor DNA (ctDNA) data from 123 atebimetinib-treated patients showed that acquired MAPK pathway alterations were rarely seen. These findings suggest that Deep Cyclic Inhibitors have the potential to overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients, while potentially preserving sensitivity to subsequent treatments.
Anticipated Upcoming Milestones
2H 2026
: Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in non-small cell lung cancer, with a preliminary data readout expected in late-2027.
Q4 2026:
Additional preclinical data of atebimetinib in combination with anti-PD-1 in non-small cell lung cancer.
Mid-2027:
Begin IND-enabling studies for our next DCI product candidate program.
Mid-2028:
Topline data readout from the MAPKeeper 301 trial.
Second
Quarter
2026
Financial Highlights
Cash Position:
Cash, cash equivalents and marketable securities as of June 30, 2026 were $182.7 million, compared with $217.0 million as of December 31, 2025.
Research and Development (R&D) Expenses:
R&D expenses for the second quarter of 2026 were $14.0 million, compared with $10.5 million for the second quarter of 2025. The change in R&D expenses was primarily attributable to increased clinical costs related to the Company’s lead atebimetinib program and spend related to other preclinical programs, partially offset by reduced spend related to the envometinib program.
General and Administrative (G&A) Expenses:
G&A expenses for the second quarter of 2026 were $5.0 million, compared with $4.3 million for the second quarter of 2025. The increase in G&A expenses was primarily attributable to employee related costs and increased software costs supporting the general and administrative functions of the business.
Net Loss:
Net loss attributable to common stockholders was $17.3 million, or $0.27 per share, for the second quarter ended June 30, 2026, compared to $14.4 million, or $0.40 per share, for the second quarter ended June 30, 2025.
2026 Financial Guidance
Based on cash, cash equivalents and marketable securities as of June 30, 2026, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into 2029.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer and its potential to deliver overall survival with both durability and tolerability; the timing of dosing and preliminary readout of the planned Phase 2 lung cancer trial and the Phase 3 topline readout of the MAPKeeper 301 trial; the timing of beginning IND-enabling studies in a second DCI program; our operating plans and anticipated cash runway, and the potential ability of the three design mechanisms of atebimetinib to shrink tumors durably, improve overall survival and overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact:
Laurence Watts
New Street Investor Relations
laurence@newstreetir.com
Media Contact:
David Caouette
dcaouette@immuneering.com
IMMUNEERING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Operating expenses
Research and development
$
13,996,647
$
10,454,160
$
24,641,869
$
21,925,852
General and administrative
4,996,444
4,296,417
9,678,939
8,302,059
Amortization of intangible asset
7,317
7,317
14,633
14,633
Total operating expenses
19,000,408
14,757,894
34,335,441
30,242,544
Loss from operations
(19,000,408
)
(14,757,894
)
(34,335,441
)
(30,242,544
)
Other income (expense)
Interest income
1,082,784
324,013
2,443,188
762,532
Other income, net
647,197
—
1,160,931
—
Net loss
$
(17,270,427
)
$
(14,433,881
)
$
(30,731,322
)
$
(29,480,012
)
Net loss per share attributable to common stockholders, basic and diluted
$
(0.27
)
$
(0.40
)
$
(0.48
)
$
(0.82
)
Weighted-average common shares outstanding, basic and diluted
64,697,219
35,985,878
64,678,120
35,759,026
Other comprehensive loss:
Unrealized loss from marketable securities
(165,235
)
—
(487,572
)
—
Comprehensive Loss
$
(17,435,662
)
$
(14,433,881
)
$
(31,218,894
)
$
(29,480,012
)
IMMUNEERING CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
June 30, 2026
December 31, 2025
Assets
Current assets:
Cash and cash equivalents
$
41,324,682
$
128,645,025
Marketable securities
108,575,637
44,186,244
Prepaids and other current assets
8,090,186
3,414,685
Total current assets
157,990,505
176,245,954
Marketable securities, non-current
32,773,479
44,183,186
Property and equipment, net
879,922
938,481
Goodwill
6,690,431
6,690,431
Intangible asset, net
306,513
321,147
Right-of-use assets
3,136,353
3,322,249
Other assets
278,124
283,562
Total assets
$
202,055,327
$
231,985,010
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$
3,377,359
$
1,542,737
Accrued expenses
4,094,874
7,842,367
Other liabilities
214,461
291,513
Lease liabilities
428,962
397,104
Total current liabilities
8,115,656
10,073,721
Long-term liabilities:
Lease liabilities, net of current portion
3,204,645
3,427,321
Total liabilities
11,320,301
13,501,042
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; 0 shares issued or outstanding at June 30, 2026 and December 31, 2025
—
—
Class A common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2026 and December 31, 2025; 64,697,402 and 64,648,230 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
64,697
64,648
Class B common stock, $0.001 par value, 20,000,000 shares authorized at June 30, 2026 and December 31, 2025; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025
—
—
Additional paid-in capital
502,127,975
498,658,072
Accumulated other comprehensive income (loss)
(406,240
)
81,332
Accumulated deficit
(311,051,406
)
(280,320,084
)
Total stockholders' equity
190,735,026
218,483,968
Total liabilities and stockholders' equity
$
202,055,327
$
231,985,010
临床2期临床结果高管变更临床3期财报
2026-07-21
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors -
- In head-to-head in vivo studies, atebimetinib produced deeper, more durable tumor growth inhibition than the FDA-approved MEK inhibitor binimetinib -
- Atebimetinib was associated with favorable tolerability in preclinical models, consistent with Deep Cyclic Inhibitor technology’s design to decouple antitumor activity from the toxicity of continuous MAPK suppression -
- In a preclinical cancer cachexia model, atebimetinib-treated animals sustained body weight near baseline through approximately two weeks of dosing, while untreated controls lost a median of more than 20% of body weight -
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the publication of new findings in Cancer Research, a leading peer-reviewed journal of the American Association for Cancer Research, characterizing the differentiated mechanism and broad preclinical activity of atebimetinib.
The article, “Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF-Bypass,” (Kolitz et al., Cancer Research, doi.org/10.1158/0008-5472.CAN-25-4907) reports that atebimetinib demonstrated broad antitumor activity across RAS- and RAF-mutant models while resisting RAF-mediated bypass signaling, a key mechanism associated with resistance to other MEK inhibitors. Because the activity observed spanned a range of KRAS, NRAS, and BRAF alterations, the findings support the potential of atebimetinib to address RAS- and RAF-mutant cancers broadly — including the majority of RAS-mutant tumors that are not addressed by currently available mutation-selective inhibitors.
“Atebimetinib was deliberately designed to overcome the historical limitations of MEK inhibition, including the toxicity that comes with chronic MAPK pathway suppression, and the RAF-mediated pathway reactivation that has limited the durability of pathway suppression, particularly in RAS-mutant disease,” said Brett Hall, Ph.D., Chief Scientific Officer of Immuneering. “The new findings noted in the Cancer Research article underscore the scientific basis for our Deep Cyclic Inhibitor technology and the broad, mutation-agnostic, durable activity we observed across RAS- and RAF-mutant models, reinforcing atebimetinib's position as a differentiated, modern MEK inhibitor.”
The article describes how atebimetinib combines a novel dual-MEK mechanism with a short half-life designed to achieve Deep Cyclic Inhibition (DCI) of the MAPK pathway. Unlike other MEK inhibitors that chronically suppress signaling and are prone to RAF-mediated bypass, atebimetinib was shown to produce profound but transient inhibition of MAPK signaling followed by recovery periods that allow normal tissue to rest between doses – an approach designed to improve tolerability while maintaining antitumor activity.
Key findings include:
Atebimetinib demonstrated potent inhibition of both pERK and pMEK across multiple KRAS-, NRAS-, and BRAF-mutant tumor models, including colorectal, lung, and melanoma models. Whereas other MEK inhibitors reduced pERK but allowed pMEK to accumulate — the molecular signature of RAF-mediated pathway reactivation — atebimetinib reduced both pERK and pMEK, reflecting its resistance to CRAF-mediated bypass. Atebimetinib’s short half-life enabled deep cyclic inhibition of the MAPK pathway, characterized by deep suppression during peak exposure followed by recovery toward physiologic baseline signaling between doses. In multiple head-to-head in vivo studies, atebimetinib demonstrated greater depth and durability of tumor growth inhibition than the FDA-approved MEK inhibitor binimetinib across KRAS-, NRAS-, and BRAF-mutant tumor models while remaining well tolerated. In the Colon-26 model, a syngeneic colon-carcinoma model widely used to study cancer cachexia, atebimetinib-treated animals maintained body weight near baseline (within approximately 5%) through roughly two weeks of dosing, while untreated control animals lost a median of more than 20% of body weight by approximately day 14. Across the in vivo models more broadly, atebimetinib-treated mice maintained body weight within a median of 3-5% over up to four weeks of chronic dosing.
Immuneering is currently recruiting patients in MAPKeeper 301 (NCT07562152), a global randomized Phase 3 pivotal trial evaluating atebimetinib plus mGnP versus standard-of-care gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer. In the second half of the year, the company expects to dose the first patient in a Phase 2 trial of atebimetinib plus Libtayo® (cemiplimab) in patients with first-line RAS-mutant non-small cell lung cancer.
About Immuneering Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer and its potential to deliver overall survival with both durability and tolerability; the timing of dosing of the MAPKeeper 301 study and the Phase 2 study in combination with Libtayo®; the ability of the three design mechanisms of atebimetinib to shrink tumors durably, improve overall survival and overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in activating trial sites or enrolling trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact: Laurence Watts laurence@newstreetir.com
Media Contact: David Caouette dcaouette@immuneering.com
临床3期临床2期临床结果AACR会议ASCO会议
2026-07-19
NEW YORK, July 17, 2026
(GLOBE NEWSWIRE)
-- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the “Start Date”). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock (“Common Stock”) with a per share exercise price of $4.78, the closing trading price of the Common Stock on the Nasdaq Global Market on July 16, 2026 (the “Closing Price”). The stock option was granted pursuant to the Company’s 2025 Employment Inducement Award Plan (the “Inducement Plan”) and was approved by the Company’s Board of Directors (the “Board”). The stock option has a ten-year term and vests (subject to Mr. Gengos’s continued service to the Company through the applicable vesting dates) as follows: 8.33333% of the initial shares underlying the option shall vest on each of the first, second and third monthly anniversary of the Start Date; 1.6667% of the initial shares underlying the option shall vest on the fourth monthly anniversary of the Start Date and on each monthly anniversary thereafter until the one-year anniversary of the Start Date; 3.33333% of the initial shares underlying the option shall vest on each monthly anniversary following the one-year anniversary of the Start Date until the second anniversary of the Start Date; and 0.833333% of the of the initial shares underlying the option shall vest on each monthly anniversary following the second anniversary of the Start Date until the fourth anniversary of the Start Date, such that the stock option shall be fully vested and exercisable on the fourth anniversary of the Start Date. The stock option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules (the “Nasdaq Rules”) as an inducement material to Mr. Gengos entering into employment with the Company.
Additionally, in connection with the commencement of employment of a non-executive employee, also on July 16, 2026, such employee was granted an option to purchase 32,400 shares of Common Stock with a per share exercise price equal to the Closing Price. The stock option was granted pursuant to the Inducement Plan and was approved by the Compensation Committee of the Board. The stock option has a ten-year term and vests (subject to the employee’s continued service to the Company through the applicable vesting dates) 25% on July 16, 2027 and the remaining 75% in substantially equal monthly installments over the three years thereafter, such that the stock option shall be fully vested and exercisable on July 16, 2030. The stock option was granted under the Nasdaq Rules as an inducement material to the employee entering into employment with the Company.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit
.
ezstandalone.cmd.push(function () {
ezstandalone.showAds(131);
});
Forward Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: Immuneering’s plans to develop, and the treatment potential of, its product candidates.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in activating trial sites or enrolling trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended March 31, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact:
Laurence Watts
laurence@newstreetir.com
Media Contact:
David Caouette
dcaouette@immuneering.com
高管变更
100 项与 atebimetinib 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性胰腺导管腺癌 | 临床3期 | 美国 | 2026-06-05 | |
| 转移性胰腺导管腺癌 | 临床3期 | 澳大利亚 | 2026-06-05 | |
| 转移性胰腺腺癌 | 临床3期 | 美国 | 2026-06-05 | |
| 转移性胰腺腺癌 | 临床3期 | 澳大利亚 | 2026-06-05 | |
| 皮肤黑色素瘤 | 临床2期 | 美国 | 2022-10-31 | |
| 转移性实体瘤 | 临床2期 | 美国 | 2022-10-31 | |
| 胰腺腺癌 | 临床2期 | 美国 | 2022-10-31 | |
| 胰腺导管腺癌 | 临床2期 | 美国 | 2022-10-31 | |
| RAS突变非小细胞肺癌 | 临床2期 | 美国 | 2022-10-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 胰腺癌 一线 | 55 | Atebimetinib 320 mg + mGnP | 壓顧膚繭艱製襯遞膚襯(簾鬱餘鬱夢鏇餘衊餘積) = 衊壓選築鹹簾積鹹衊築 廠鏇鏇餘淵顧顧糧鬱醖 (鹽廠衊壓鑰製鹹淵獵積 ) 更多 | 积极 | 2026-05-29 | |
Biospace 人工标引  | 临床1/2期 | 127 | 襯膚願鹹鹽願願鏇鏇繭(願壓壓範衊壓餘築憲願) = 衊鹽顧鬱窪醖網糧獵繭 蓋蓋遞願艱鏇淵顧築獵 (餘繭遞窪鑰廠範艱廠遞 ) 更多 | 积极 | 2025-09-25 | ||
standard of care | 襯膚願鹹鹽願願鏇鏇繭(願壓壓範衊壓餘築憲願) = 鏇艱網選壓簾齋製鹹鏇 蓋蓋遞願艱鏇淵顧築獵 (餘繭遞窪鑰廠範艱廠遞 ) 更多 | ||||||
临床2期 | 胰腺癌 一线 | - | Atebimetinib (320mg dosed once-daily)Atebimetinib (320mg dosed once-daily) + mGnP (modified gemcitabine/nab-paclitaxel (mGnP)) | 鏇範憲願鹽範製觸選廠(鏇艱鑰餘鏇齋壓獵齋鬱) = 衊齋選鹹願繭選廠築壓 蓋廠齋壓網廠獵願積繭 (糧衊餘夢憲窪獵積選網 ) 更多 | 积极 | 2025-09-24 | |
鏇範憲願鹽範製觸選廠(鏇艱鑰餘鏇齋壓獵齋鬱) = 衊鏇淵憲窪鏇積艱顧壓 蓋廠齋壓網廠獵願積繭 (糧衊餘夢憲窪獵積選網 ) 更多 | |||||||
临床2期 | 胰腺癌 一线 | 50 | Atebimetinib + mGnP at 320 mg dose level | 獵構窪齋衊壓觸膚鏇築(鬱窪廠鏇醖製鑰顧襯構) = 選鹽構繭壓鬱簾製遞構 願襯願糧齋遞膚顧製繭 (範願艱淵醖糧築醖餘襯 ) 更多 | 积极 | 2025-06-17 | |
Standard of care treatment (full dose and schedule GnP) | 獵構窪齋衊壓觸膚鏇築(鬱窪廠鏇醖製鑰顧襯構) = 餘遞鬱衊衊醖構糧鏇醖 願襯願糧齋遞膚顧製繭 (範願艱淵醖糧築醖餘襯 ) 更多 | ||||||
临床2期 | 胰腺癌 一线 | 6 | IMM-1-104 in combination with modified FOLFIRINOX (mFFX) | 膚遞簾蓋顧願糧鑰鹽繭(鹽網獵窪鬱鏇鬱網蓋蓋) = 蓋顧遞築鹽艱獵遞夢簾 選窪艱製廠顧艱獵蓋獵 (膚願蓋積憲鹽襯築構夢 ) | 积极 | 2025-01-13 | |
FOLFIRINOX (historic benchmark) | 膚遞簾蓋顧願糧鑰鹽繭(鹽網獵窪鬱鏇鬱網蓋蓋) = 選膚築築廠鑰窪構遞齋 選窪艱製廠顧艱獵蓋獵 (膚願蓋積憲鹽襯築構夢 ) | ||||||
临床2期 | - | (First Line) | 廠艱範簾積願鹹衊遞繭(製鬱選齋鹽鹹範積願願) = 鹽廠鹽餘築網製顧鬱壓 範製遞蓋積糧憲淵鏇鏇 (鏇醖夢淵選鏇鬱範簾觸 ) 更多 | 积极 | 2025-01-07 | ||
IMM-1-104 + modified FOLFIRINOX (First Line) | 廠艱範簾積願鹹衊遞繭(製鬱選齋鹽鹹範積願願) = 糧製鬱衊繭糧淵網衊繭 範製遞蓋積糧憲淵鏇鏇 (鏇醖夢淵選鏇鬱範簾觸 ) | ||||||
临床2期 | 5 | 壓築簾鹽鏇顧範淵壓簾(積衊選衊壓憲鹹願鏇顧) = 鑰夢鑰醖選糧簾遞繭齋 鏇觸網願憲艱獵憲鹽壓 (製淵齋願醖餘繭顧觸憲 ) 更多 | 积极 | 2024-09-12 | |||
临床1/2期 | 实体瘤 RAS Mutation (Activating) | 41 | 範網夢齋選夢顧積製願(憲衊醖醖觸製齋鬱窪願) = MM-1-104 has been well-tolerated, with the potential for a differentiated safety profile. 構襯鹽憲壓網鑰憲鹽醖 (鏇齋網願積醖齋範糧鹹 ) 更多 | 积极 | 2024-03-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用